Servicio de Dermatología. Hospital Universitario de Gran Canaria Doctor Negrín. Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España
Auto-generated profile, based on publicly available information
Carlos Pelayo Hernández Fernández
Servicio de Dermatología. Hospital Universitario de Gran Canaria Doctor Negrín. Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España
Background: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. Objectives: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. Methods: We conducted a retrospective study. We performed an electronic and manual chart review of patients treated with MTX in the Psoriasis Unit of our Hospital from January 2007 to December 2014. Demographic and clinical data, PASI/DLQI scores and reasons for suspension of all patients treated with MTX in usual clinical practice were recorded. Results: Two hundred and eighteen patients were included. MTX was administered in 67% of cases as the first systemic treatment. The average treatment duration was 17.2 ± 13.6 months. All patients were subjected to clinical and laboratory monitoring. About 33.5% of them achieved a reduction of 75% or more of the initial PASI at week 12, 34.9% at week16, 44.7% at week 24, and 52.8% at week 48. A 3.3% had to discontinue the therapy due to analytical hepatic (2.8%) or renal (0.5%) abnormalities. Only one patient experienced severe interstitial pneumonitis and none required liver biopsy. Conclusions: MTX is an effective and safe option for the treatment of psoriasis in the real-world clinical practice.
Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown.Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para‐phenylenediamine (PPD) and specific disperse dyes.Materials and Methods: We analysed all consecutive patients patch‐tested with TDM from the Spanish Contact Dermatitis Registry (REIDAC), from 1 January 2019 to 31 December 2022. Within this group, we studied all selected patients patch‐tested with a textile dye series.Results: Out of 6128 patients analysed, 3.3% were positive to the TDM and in 34% of them, the sensitization was considered currently relevant. TDM positivity was associated with working as a hairdresser/beautician and scalp, neck/trunk and arm/forearm dermatitis. From TDM‐positive patients, 57% were positive to PPD. One hundred and sixty‐four patients were patch‐tested with the textile dye series. Disperse Orange 3 was the most frequent positive dye (16%). One of every six cases positive to any dye from the textile dye series would have been missed if patch‐tested with the TDM alone.Conclusions: Positivity to TDM is common in Spain and often associated with PPD sensitization. TDM is a valuable marker of disperse dyes allergy that should be part of the Spanish and European standard series.
Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral® is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish standard path test series. We analysed all consecutive patients simultaneously patch-tested with HICC and FM II from the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 through December 31st, 2023. A total of 96 (0.8%) out of 12,029 patients analyzed tested positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II were patched. Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish standard patch test series and support its exclusion from the European standard patch test series.